CareDx Inc (CDNA)
| Bid | 18.86 |
| Market Cap | 1.05B |
| Revenue (ttm) | 333.79M |
| Net Income (ttm) | 52.55M |
| EPS (ttm) | 0.93 |
| PE Ratio (ttm) | 20.33 |
| Forward PE | 40.07 |
| Analyst | Buy |
| Ask | 19.03 |
| Volume | 406,026 |
| Avg. Volume (20D) | 832,391 |
| Open | 19.25 |
| Previous Close | 18.81 |
| Day's Range | 18.58 - 19.32 |
| 52-Week Range | 7.42 - 34.84 |
| Beta | 2.18 |
About CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The co...
Analyst Forecast
According to 7 analyst ratings, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $33.5, which is an increase of 77.15% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
CareDx Launches Two Expanded Indications for AlloSure Testing ServicesBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...
1 month ago · businesswire.com
CareDx Announces Fourth Quarter and Full Year 2024 Financial ResultsBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights Revenu...
